These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 14685670)

  • 1. [Drug resistance in antiretroviral therapy of HIV infection].
    Oette M; Häussinger D
    Med Klin (Munich); 2003 Dec; 98(12):692-9. PubMed ID: 14685670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies.
    Todesco E; Sayon S; Fourati S; Tubiana R; Simon A; Ktorza N; Schneider L; Peytavin G; Malet I; Van den Eede P; Katlama C; Calvez V; Marcelin AG; Wirden M
    J Antimicrob Chemother; 2013 Dec; 68(12):2882-9. PubMed ID: 23873645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing.
    Casadellà M; Noguera-Julian M; Sunpath H; Gordon M; Rodriguez C; Parera M; Kuritzkes DR; Marconi VC; Paredes R
    AIDS; 2016 Apr; 30(7):1137-40. PubMed ID: 26807968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa.
    Inzaule SC; Ondoa P; Peter T; Mugyenyi PN; Stevens WS; de Wit TFR; Hamers RL
    Lancet Infect Dis; 2016 Nov; 16(11):e267-e275. PubMed ID: 27569762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation.
    Godfrey C; Thigpen MC; Crawford KW; Jean-Phillippe P; Pillay D; Persaud D; Kuritzkes DR; Wainberg M; Raizes E; Fitzgibbon J
    J Infect Dis; 2017 Dec; 216(suppl_9):S798-S800. PubMed ID: 28973412
    [No Abstract]   [Full Text] [Related]  

  • 6. In Defense of Baseline Genotypic Antiretroviral Resistance Testing.
    Lang R; Krentz HB; Gill MJ
    J Acquir Immune Defic Syndr; 2020 Jan; 83(1):e1-e2. PubMed ID: 31809365
    [No Abstract]   [Full Text] [Related]  

  • 7. Deep sequencing for HIV-1 clinical management.
    Casadellà M; Paredes R
    Virus Res; 2017 Jul; 239():69-81. PubMed ID: 27818211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rethinking recycling nucleoside reverse transcriptase inhibitors in HIV treatment: learning from dual therapy studies.
    Ripamonti D; Zazzi M
    AIDS; 2018 Apr; 32(7):835-840. PubMed ID: 29424781
    [No Abstract]   [Full Text] [Related]  

  • 9. HIV drug resistance in Africa: an emerging problem that deserves urgent attention.
    Moreno M; Caballero E; Mateus RM; Samba F; Gil E; Falcó V
    AIDS; 2017 Jul; 31(11):1637-1639. PubMed ID: 28481772
    [No Abstract]   [Full Text] [Related]  

  • 10. Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance.
    Bandera A; Gori A; Clerici M; Sironi M
    Curr Opin Pharmacol; 2019 Oct; 48():24-32. PubMed ID: 31029861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of Madagascar's HIV/AIDS reference laboratory.
    Andriantsimietry SH; Razanakolona RL
    Med Mal Infect; 2016 May; 46(3):146-9. PubMed ID: 27132210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promises and pitfalls of Illumina sequencing for HIV resistance genotyping.
    Brumme CJ; Poon AFY
    Virus Res; 2017 Jul; 239():97-105. PubMed ID: 27993623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Research development of HIV drug resistance].
    Zou W; Liu Y; Wang J; Gao GJ; Dong JP; Xian QF
    Zhongguo Zhong Yao Za Zhi; 2013 Aug; 38(15):2542-4. PubMed ID: 24228557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using drug exposure for predicting drug resistance - A data-driven genotypic interpretation tool.
    Pironti A; Pfeifer N; Walter H; Jensen BO; Zazzi M; Gomes P; Kaiser R; Lengauer T
    PLoS One; 2017; 12(4):e0174992. PubMed ID: 28394945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline HIV genotype drug resistance testing: is it time for more or less?
    Wood BR; Stekler JD
    AIDS; 2022 Aug; 36(10):1449-1451. PubMed ID: 35876702
    [No Abstract]   [Full Text] [Related]  

  • 16. Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance.
    Duarte HA; Panpradist N; Beck IA; Lutz B; Lai J; Kanthula RM; Kantor R; Tripathi A; Saravanan S; MacLeod IJ; Chung MH; Zhang G; Yang C; Frenkel LM
    J Infect Dis; 2017 Dec; 216(suppl_9):S824-S828. PubMed ID: 29040621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choosing appropriate pharmacotherapy for drug-resistant HIV.
    Capetti A; Rizzardini G
    Expert Opin Pharmacother; 2019 Apr; 20(6):667-678. PubMed ID: 30676115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized HIV therapy to control drug resistance.
    Lengauer T; Pfeifer N; Kaiser R
    Drug Discov Today Technol; 2014 Mar; 11():57-64. PubMed ID: 24847654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conflicting Selection Pressures Will Constrain Viral Escape from Interfering Particles: Principles for Designing Resistance-Proof Antivirals.
    Rast LI; Rouzine IM; Rozhnova G; Bishop L; Weinberger AD; Weinberger LS
    PLoS Comput Biol; 2016 May; 12(5):e1004799. PubMed ID: 27152856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PhyloPi: An affordable, purpose built phylogenetic pipeline for the HIV drug resistance testing facility.
    Bester PA; De Vries A; Riekert S; Steegen K; van Zyl G; Goedhals D
    PLoS One; 2019; 14(3):e0213241. PubMed ID: 30835760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.